Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent

National Center For Advancing Translational Sciences

Investigators

Linked publications, trials & patents

Abstract

The NCATS Early Translation Branch (ETB) hosts a broad and comprehensive program for the discovery of drug candidates directed towards rare diseases and pharmacological tools to probe the function of the human genome. ETB conducts research to understand the underlying principles driving the translation of basic research discoveries into tangible improvements in human health. During this reporting period, the collaborative team has worked to optimize the best validated hit from the primary screen. This screening resulted in obtaining the first potent and selective RXFP2 agonists with good pharmacokinetic properties. Initial evaluation in mice models of osteoporosis resulted in good efficacy.